Adaptive Biotechnologies Corp (ADPT)

Currency in USD
14.790
-0.770(-4.95%)
Closed·
14.820+0.030(+0.20%)
·

ADPT Earnings

Latest Release
Nov 05, 2025
EPS / Forecast
0.06 / -0.17
Revenue / Forecast
93.97M / 60.48M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/-0.163--/64.61M----Free Sign Up
09/20250.06/-0.1793.97M/60.48M+135.29%+55.37%Free Sign Up
06/2025-0.17/-0.2458.88M/49.4M+29.17%+19.19%Free Sign Up
03/2025-0.2/-0.2952.44M/42.81M+31.03%+22.49%Free Sign Up
12/2024-0.23/-0.2547.46M/46.15M+8%+2.84%Free Sign Up
09/2024-0.22/-0.2946.4M/40.21M+24.14%+15.39%Free Sign Up
06/2024-0.31/-0.3343.19M/38.63M+6.06%+11.8%Free Sign Up
03/2024-0.33/-0.3541.87M/38.79M+5.71%+7.94%Free Sign Up
12/2023-0.48/-0.345.78M/48.45M-60%-5.51%Free Sign Up
09/2023-0.35/-0.3437.92M/42.96M-2.94%-11.73%Free Sign Up

All numbers in USD

Adaptive Biotechnologies Corp Earnings Call Summary for Q3/2025

  • Adaptive Biotechnologies reported Q3 2025 EPS of $0.06 vs forecast of -$0.17, with revenue reaching $94M (up 102% YoY), exceeding expectations by 55.37%.
  • MRD business achieved cash flow positivity, driving the company to raise full-year MRD revenue guidance to $202-207M with anticipated 104,000 tests for 2025.
  • Adjusted EBITDA improved significantly to $28M from -$14.3M last year, with the company maintaining a strong cash position of $217M at quarter-end.
  • Following earnings release, stock rose 3.96% to $16.92 and continues trading near its 52-week high of $17.89, reflecting strong investor confidence.
  • CEO Chad Robins highlighted MRD as 'a profitable scaling business delivering consistent growth and margin expansion,' despite potential challenges from emerging competition.
Last Updated: 05/11/2025, 23:50
Read Full Transcript

FAQ

What Is Adaptive Biotechnologies's Earnings Per Share (TTM)?

The Adaptive Biotechnologies EPS (TTM) is -0.53.

When Is The Next Adaptive Biotechnologies Earnings Date?

Adaptive Biotechnologies will release its next earnings report on 16 Feb 2026.

What Is Adaptive Biotechnologies’s Revenue Forecasts For Upcoming Quarters?

Adaptive Biotechnologies’s revenue forecast is 64.61M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.